Middle East and Africa Point
Market Size in USD Billion
CAGR :
% 
 予測期間 |
2024 –2031 |
 市場規模（基準年） |
USD 61.20 Million |
 Market Size (Forecast Year) |
USD 78.11 Million |
 CAGR |
% |
| 主要市場プレーヤー |
Middle East and Africa Point-of-Care (POC) Drug Abuse Testing Market, By Drug Type (Amphetamines, Opiates, Cannabinoids, Cocaine, Barbiturates, Benzodiazepines, Methadone, Phencyclidine, Tricyclic Antidepressants, and Others), Products (Devices and Consumables and Accessories), Prescription (Over the Counter Testing and Prescription-Based Testing), Sample Type (Urine, Saliva, Blood, Hair, Breath, and Others), Testing Type (Random Testing, Post-Incident Testing, and Abstinence Testing), Application (Medical Screening, Workplace Screening, Law Enforcement and Criminal Justice, Pain Management, Substance Abuse Treatment and Rehabilitation, Parental or Home Drug Testing, Sports and Athletics Testing, Drug Screening in Schools and Educational Institutions, and Others), End User (Healthcare Facilities, Employers, Government Institutes, and Others), Distribution Channel (Direct Tender, Retails Sales, and Others) - Industry Trends and Forecast to 2031.
Middle East and Africa Point-of-Care (POC) Drug Abuse Testing Market Analysis and Size
The market is driven by increasing awareness and emphasis on drug abuse prevention and management, along with the growing need for quick and accurate drug testing in diverse environments. Key factors fueling market growth include rising drug abuse rates, stringent regulatory requirements for drug testing in workplaces, and advancements in POC testing technologies that offer enhanced accuracy and user convenience. Additionally, the growing prevalence of substance abuse disorders across different demographics contributes to the demand for effective and accessible drug testing solutions.
The Middle East and Africa Point-of-Care (POC) drug abuse testing market encompasses a range of diagnostic technologies and solutions designed to detect the presence of illicit substances or controlled drugs in an individual’s system at the location of care, rather than in a traditional laboratory setting. These tests provide rapid, on-the-spot results, which are crucial for timely decision-making and intervention in various settings such as medical facilities, emergency rooms, workplaces, and even in home settings. The market includes devices and testing kits for detecting drugs in urine, saliva, blood, and other biological samples.
Data Bridge Market Research analyzes that the Middle East and Africa Point-of-Care (POC) drug abuse testing market is expected to reach USD 78.11 million by 2031 from USD 61.20 million in 2023, growing with a CAGR of 3.3% in the forecast period of 2024 to 2031.
|
Report Metric |
Details |
|
Forecast Period |
2024 to 2031 |
|
Base Year |
2023 |
|
Historic Years |
2022 (Customizable 2016-2021) |
|
Quantitative Units |
Revenue in USD Million |
|
Segments Covered |
Drug Type (Amphetamines, Opiates, Cannabinoids, Cocaine, Barbiturates, Benzodiazepines, Methadone, Phencyclidine, Tricyclic Antidepressants, and Others), Products (Devices and Consumables and Accessories), Prescription (Over the Counter Testing and Prescription-Based Testing), Sample Type (Urine, Saliva, Blood, Hair, Breath, and Others), Testing Type (Random Testing, Post-Incident Testing, and Abstinence Testing), Application (Medical Screening, Workplace Screening, Law Enforcement and Criminal Justice, Pain Management, Substance Abuse Treatment and Rehabilitation, Parental or Home Drug Testing, Sports and Athletics Testing, Drug Screening in Schools and Educational Institutions, and Others), End User (Healthcare Facilities, Employers, Government Institutes, and Others), Distribution Channel (Direct Tender, Retails Sales, and Others) |
|
Countries Covered |
South Africa, Egypt, Saudi Arabia, U.A.E., Israel, Kuwait, and Rest of Middle East and Africa |
|
Market Players Covered |
Abbott Laboratories, Quest Diagnostics Incorporated, Thermo Fisher Scientific, Inc., F.Hoffman-La Roche Ltd., Siemens Healthineers AG, MP Biomedicals., Beijing Hotgen Biotechn Co., LTD., Assure Tech (Hangzhou) co., ltd., Accubio Tech Co., ltd. Premier biotech,inc., Wondfo and, among others |
Market Definition
Point-of-Care (PoC) drug abuse testing refers to rapid screening methods used to detect the presence of drugs or their metabolites in a person's system at the site of care, such as clinics or emergency rooms. These tests provide quick results, enabling timely decision-making for treatment or intervention. Typically involving urine, saliva, or blood samples, PoC testing is essential for monitoring substance use, ensuring patient safety, and facilitating access to appropriate support services.
Middle East and Africa Point-of-Care (POC) Drug Abuse Testing Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail as below:
Drivers
- Rising Incidence of Drug Abuse
Drug abuse involving opiates, cannabinoids, and amphetamines has been growing regionally, creating a public health crisis that requires immediate and scalable solutions. Healthcare providers, law enforcement agencies, and employers are increasingly relying on POC drug testing as it offers rapid, accurate, and on-site detection, which is critical in managing the consequences of drug abuse.
In healthcare, the need for quick detection of drug abuse is essential to offer timely interventions, especially in emergency cases or rehabilitation centers. In law enforcement, the ability to test individuals on-site accelerates decision-making and enhances efforts to curb drug-related crimes. Similarly, workplaces are adopting POC drug testing to maintain a drug-free environment, reduce liability, and comply with safety regulations.
Technological advancements in POC testing devices further support the growing demand for rapid, reliable testing methods. These devices are becoming more portable, user-friendly, and capable of detecting a wide range of substances, making them ideal for use in non-laboratory settings.
For instance,
- In January 2024, according to an article published by NCBI, Opioid Use Disorder (OUD) affects over 16 million people worldwide, including 2.1 million in the U.S., leading to more than 120,000 deaths regionally each year. The prevalence of opioid use and dependency is high, with up to 50% of long-term opioid users meeting OUD criteria. The rising incidence of opioid-related issues drives the need for effective drug testing solutions, thereby fuelling growth in the Middle East and Africa Point-of-Care (POC) drug abuse testing market
- In August 2023, according to an article published by WHO, in 2019, approximately 600,000 deaths regionally were linked to drug use, with about 80% related to opioids. Of these, around 125,000 were due to opioid overdose, while non-fatal overdoses are significantly more common. The rise in opioid overdoses is attributed to increased opioid availability for chronic pain management and the presence of potent opioids on the illicit market. In the USA, drug overdose deaths totaled 70,630 in 2019, with synthetic opioids involved in about half of these cases.
Growth in Home and Parental Drug Testing Kits
The growing demand for easy-to-use, over-the-counter drug testing kits for home use reflects a strong consumer preference for privacy and convenience in monitoring substance use. Parents are increasingly adopting these kits to detect and prevent substance abuse among teenagers, while individuals are opting for self-testing options for personal reasons.
Technological advancements have led to the creation of more accurate, reliable, and user-friendly drug testing products, enabling consumers to perform tests privately at home without professional assistance. This convenience reduces the stigma associated with drug testing, fostering wider adoption of these solutions. Home testing kits are now more sensitive and capable of detecting a broad range of drugs, providing results that are comparable to those from laboratory tests.
Increased awareness of substance abuse and the easy availability of these kits through pharmacies and online platforms are contributing to market growth. The trend is further supported by a growing preference for non-invasive sample collection methods, such as saliva or urine tests, which are simple to use at home.
For instance,
- In November 2023, according to an article published by DNA Forensics Laboratory Pvt. Ltd., in recent years, at-home drug testing kits have become increasingly popular due to their convenience and ease of access. These kits enable individuals to conduct drug tests privately at home, typically including test strips or collection devices along with clear instructions for sample collection and result interpretation. This trend towards home testing highlights the "growth in home and parental drug testing kits" and drives the demand for such products. The growing preference for private and convenient drug testing solutions propels the expansion of the Middle East and Africa Point-of-Care (POC) drug abuse testing market.
In conclusion, the rising demand for home and parental drug testing kits is driving significant growth in the POC drug abuse testing market by offering consumers private, convenient, and reliable options for substance abuse monitoring, fueling expansion in this segment.
Opportunity
- Growing Awareness and the Campaign for Drug Testing
The increasing awareness surrounding the dangers of drug abuse, coupled with robust public health campaigns and government support, presents a significant opportunity for growth in the Middle East and Africa Point-of-Care (POC) drug abuse testing market. As society becomes more cognizant of the detrimental impacts of substance abuse, there is a growing demand for accessible and effective testing solutions. Public health campaigns, often spearheaded by governmental and non-governmental organizations, play a crucial role in educating communities about the importance of early detection and intervention. These initiatives not only amplify the visibility of drug abuse issues but also advocate for the use of point-of-care testing as a preventive measure. Furthermore, government support through funding and policy-making enhances the accessibility of POC drug testing solutions by promoting regulatory frameworks that facilitate the adoption of these technologies in various settings, including workplaces, schools, and public health programs. The combination of heightened awareness and strategic support fosters an environment conducive to market expansion, driving innovation and increasing the availability of advanced testing solutions to address the evolving needs of society.
- In December 2023, according to the article published by the Greater London Authority, UK government allocated USD 1.54 million to this mission, focusing on testing for 14 different drugs with the rising awareness and proactive government initiatives in the UK have led to the implementation of random mandatory drug testing for individuals released from prison, aiming to reduce crime rates. This move underscores the nation's commitment to tackling substance abuse and its impact on criminal behavior, reflecting broader efforts to enhance public safety and well-being.
- In July 2021, according to the article published by Commonwealth of Australia and the Department of Health and Aged Care, the Australian government launched the National Ice Action Strategy, which included significant investments to enhance Point-of-Care (POC) drug abuse testing. This initiative aimed to curb the growing use of methamphetamines, commonly known as "ice," by providing law enforcement and healthcare providers with more accessible and accurate drug testing tools. The strategy also focused on expanding the availability of POC testing in remote and rural areas, ensuring that communities across the country could benefit from timely and effective drug detection and intervention measures.
Hence, the convergence of growing awareness, active public health campaigns, and strong government support is poised to significantly benefit the Middle East and Africa Point-of-Care (POC) drug abuse testing market. This dynamic environment not only promotes the adoption of drug testing technologies but also encourages the development of more sophisticated and accessible solutions. As these factors continue, the future of POC drug abuse testing looks promising, with enhanced opportunities for innovation, broader market reach, and improved public health outcomes.
Restraint/Challenge
- High Costs Associated with the Testing
The complexity of developing reliable and accurate POC drug abuse tests often requires advanced technology, specialized materials, and rigorous validation processes, all of which contribute to elevated production costs. These costs are further compounded by stringent regulatory requirements, as ensuring compliance with international standards demands extensive testing, quality control, and documentation, adding to the overall expense. Additionally, the need for consistent research and development to keep pace with emerging drug abuse patterns and to enhance the sensitivity and specificity of these tests drives up the costs even more. For healthcare providers, the high upfront investment required to integrate these testing solutions into their practices can be prohibitive, particularly for smaller clinics or organizations with limited budgets. This financial burden can deter the adoption of POC drug abuse testing despite its potential benefits in terms of speed and convenience. The situation is exacerbated in low- and middle-income countries, where healthcare budgets are already strained, and the added cost of POC testing can be a barrier to implementation, limiting the market's expansion into these regions. Moreover, the high cost can lead to disparities in healthcare access, as only well-funded institutions may be able to afford these advanced testing methods, leaving vulnerable populations without adequate testing and care. This challenge is not only a financial one but also an ethical issue, as the inability to provide affordable testing solutions undermines the efforts to combat drug abuse on a broader scale.
For instance,
- In May 2023, according to an article published by the National Library of Medicine, POC testing was costlier performed on an individual basis when compared to traditional laboratory testing due to the single-use nature of most POCT devices, which adds to the overall expenses.
- In January 2024, according to an article published by Checkr., the cost of drug testing for comprehensive laboratory panels can exceed USD 500. Onsite tests typically range from USD 20 to USD 40, but the need for lab confirmation can drive prices up, starting at USD 50 and varying based on the test type and substances screened. High volumes of tests might reduce the average cost per test, but the overall expense can still be substantial.
Hence, the high cost of POC drug abuse testing creates significant barriers to its broader adoption, limiting accessibility, especially in resource-constrained regions. This financial challenge not only hampers market growth but also exacerbates healthcare inequalities, preventing many from receiving timely and effective drug abuse testing, and is expected to act as a challenge for market growth in the future.
Recent Developments
- In August 2024, Abbott announced a Middle East and Africa partnership with Medtronic on August 7, 2024, to integrate Abbott's advanced FreeStyle Libre Continuous Glucose Monitoring (CGM) technology with Medtronic's insulin delivery systems. This collaboration aimed to enable automatic insulin adjustments and improve diabetes management, benefiting over 11 million people worldwide. Financial terms were undisclosed
- In March 2024, Abbott extended its partnership with Real Madrid and the Real Madrid Foundation through the 2026-2027 season, continuing as their Middle East and Africa health sciences and nutrition partner. Since 2021, Abbott provided over 25,000 hours of nutrition education and screened more than 3,000 children for malnutrition
- In August 2023, SSM Health, Siemens Healthineers partner to advance health equity and empower workforce development in underserved communities. The partnership with SSM Health benefits Siemens Healthineers by expanding its market presence, increasing visibility of its technology, fostering long-term growth, and enhancing its reputation in the healthcare sector
- In February 2024, Roche entered into collaboration agreement with PathAI to expand digital pathology capabilities for companion diagnostics. The collaboration provides Roche with PathAI’s advanced AI technology for improving companion diagnostics. It ensures exclusive, tailored solutions and accelerates algorithm development while allowing Roche to continue developing its own diagnostics
- In November 2023, Roche launched next-generation qPCR system to advance clinical needs in molecular diagnostics and address public health challenges. Roche’s next-generation qPCR system boosts its market position, meets clinical and public health needs, and opens new revenue opportunities while showcasing its commitment to innovation
Middle East and Africa Point-of-Care (POC) Drug Abuse Testing Market Scope
The Middle East and Africa Point-of-Care (POC) drug abuse testing market is segmented into eight notable segments based on drug type, products, prescription, sample type, testing type, application, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.
Drug Type
- Amphetamines
- Opiates
- Cannabinoids
- Cocaine
- Barbiturates
- Benzodiazepines
- Methadone
- Phencyclidine
- Tricyclic Antidepressants
- Others
On the basis of drug type, the market is segmented into amphetamines, cannabinoids, opiates, cocaine, benzodiazepines, barbiturates, phencyclidine, methadone, tricyclic antidepressants, and others.
Products
- Devices
- Consumables and Accessories
On the basis of products, the market is segmented into devices and consumables and accessories.
Prescription
- Over the Counter Testing
- Prescription-Based Testing
On the basis of prescription mode, the market is segmented into prescription-based testing, and over the counter testing.
Sample Type
- Urine
- Saliva
- Blood
- Hair
- Breath
- Others
On the basis of sample type, the market is segmented into urine, saliva, blood, hair, breath, and others.
Testing Type
- Random Testing
- Post-Incident Testing
- Abstinence Testing
On the basis of testing type, the market is segmented into random testing, post-incident testing, and abstinence testing.
Application
- Medical Screening
- Workplace Screening
- Law Enforcement and Criminal Justice
- Pain Management
- Substance Abuse Treatment and Rehabilitation
- Parental or Home Drug Testing
- Sports and Athletics Testing
- Drug Screening in Schools and Educational Institutions
- Others
On the basis of application, the market is segmented medical screening, workplace screening, law enforcement and criminal justice, pain management, substance abuse treatment and rehabilitation, parental or home drug testing, sports and athletics testing, drug screening in schools and educational institutions, and others.
End User
- Healthcare Facilities
- Employers
- Government Institutes
- Others
On the basis of end user, the market is segmented into healthcare facilities, employers, government institute, and others.
Distribution Channel
- Direct Tender
- Retail Sales
- Others
On the basis of distribution channel, the market is segmented into direct tender, retails sales, and others.
Middle East and Africa Point-of-Care (POC) Drug Abuse Testing Market Regional Analysis/Insights
Middle East and Africa Point-of-Care (POC) drug abuse testing market is analyzed, and market size insights and trends are provided by based on drug type, products, prescription, sample type, testing type, application, end user, distribution channel as referenced above.
The countries covered in this market report are South Africa, Egypt, Saudi Arabia, U.A.E., Israel, Kuwait, and rest of Middle East and Africa
Saudi Arabia is expected to dominate in the Middle East and Africa market due to rising use of POC testing in healthcare facilities.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of regional brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Middle East and Africa Point-of-Care (POC) Drug Abuse Testing Market Share Analysis
The Middle East and Africa Point-of-Care (POC) drug abuse testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, regional presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on the Middle East and Africa Point-of-Care (POC) drug abuse testing market.
Some of the major players operating in the Middle East and Africa Point-of-Care (POC) drug abuse testing market are Abbott Laboratories, Quest Diagnostics Incorporated, Thermo Fisher Scientific, Inc., F.Hoffman-La Roche Ltd., Siemens Healthineers AG, MP Biomedicals., Beijing Hotgen Biotechn Co., LTD., Assure Tech (Hangzhou) co., ltd., Accubio Tech Co., ltd. Premier biotech,inc., and Wondfo, among others.
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTERS FIVE FORCES ANALYSIS
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 RISING INCIDENCE OF DRUG ABUSE
5.1.2 GROWING EMPHASIS ON WORKPLACE SAFETY
5.1.3 GROWTH IN HOME AND PARENTAL DRUG TESTING KITS
5.1.4 RISING USE OF POC TESTING IN HEALTHCARE FACILITIES
5.2 RESTRAINTS
5.2.1 DATA SECURITY AND PRIVACY CONCERNS
5.2.2 LACK OF ACCURACY AND TECHNICAL CHALLENGES
5.3 OPPORTUNITIES
5.3.1 GROWING AWARENESS AND THE CAMPAIGN FOR DRUG TESTING
5.3.2 STRATEGIC INITIATION AND DECISION TAKEN BY THE MARKET PLAYERS
5.3.3 EXPANDING PRODUCT RANGE FOR POINT-OF-CARE DRUG ABUSE TESTING
5.4 CHALLENGES
5.4.1 LIMITED AWARENESS AND ACCEPTANCE
5.4.2 HIGH COSTS ASSOCIATED WITH THE TESTING
6 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE
6.1 OVERVIEW
6.2 AMPHETAMINES
6.3 OPIATES
6.4 CANNABINOIDS
6.5 COCAINE
6.6 BARBITURATES
6.7 BENZODIAZEPINES
6.8 METHADONE
6.9 PHENCYCLIDINE
6.1 TRICYCLIC ANTIDEPRESSANTS
6.11 OTHERS
7 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS
7.1 OVERVIEW
7.2 DEVICES
7.2.1 ANALYZER
7.2.1.1 IMMUNOASSAY ANALYZER
7.2.1.1.1 HIGH VOLUME
7.2.1.1.2 MID VOLUME
7.2.1.1.3 LOW VOLUME
7.2.1.2 BREATHALYZER
7.2.1.2.1 ELECTROCHEMICAL FUEL CELL BREATH ANALYZERS
7.2.1.2.2 INFRARED OPTICAL SENSOR BREATH ANALYZERS
7.2.1.2.3 SEMICONDUCTOR BREATH ANALYZERS
7.2.2 RAPID DEVICES
7.2.3 DRUG TESTING CASSETTE
7.2.4 DRUG TESTING CUPS
7.2.5 DIP CARDS/STRIPS
7.2.6 ORAL FLUID TESTING DEVICES
7.2.7 OTHERS
7.2.8 MODALITY
7.2.9 HANDHELD
7.2.10 MOBILE
7.2.11 MANUAL
7.2.12 AUTOMATED
7.3 CONSUMABLES AND ACCESSORIES
7.3.1 ASSAY KITS AND REAGENTS
7.3.2 PROBES
7.3.3 OTHERS
7.3.3.1 DAST-10
7.3.3.2 Plasma Protein Binding
7.3.3.3 Plasma and Serum Stability
7.3.3.4 Others
7.3.3.4.1 Multi-Panel Drug Test Kits
7.3.3.4.2 Single-Panel Drug Test Kits
8 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION
8.1 OVERVIEW
8.2 OVER THE COUNTER TESTING
8.3 PRESCRIPTION-BASED TESTING
9 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE
9.1 OVERVIEW
9.2 URINE
9.3 SALIVA
9.4 BLOOD
9.5 HAIR
9.6 BREATH
9.7 OTHERS
10 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE
10.1 OVERVIEW
10.2 RANDOM TESTING
10.3 POST-INCIDENT TESTING
10.4 ABSTINENCE TESTING
11 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION
11.1 OVERVIEW
11.2 MEDICAL SCREENING
11.3 WORKPLACE SCREENING
11.4 LAW ENFORCEMENT AND CRIMINAL JUSTICE
11.5 PAIN MANAGEMENT
11.6 SUBSTANCE ABUSE TREATMENT AND REHABILITATION
11.7 PARENTAL OR HOME DRUG TESTING
11.8 SPORTS AND ATHLETICS TESTING
11.9 DRUG SCREENING IN SCHOOLS AND EDUCATIONAL INSTITUTIONS
11.1 OTHERS
12 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER
12.1 OVERVIEW
12.2 HEALTHCARE FACILITIES
12.2.1 HOSPITALS
12.2.2 EMERGENCY DEPARTMENT
12.2.3 CENTRAL LABS
12.2.4 CLINICS
12.2.5 POISON CONTROL CENTERS
12.2.6 OTHERS
12.3 EMPLOYERS
12.4 GOVERNMENT INSTITUTES
12.5 OTHERS
13 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 RETAIL SALES
13.4 OTHERS
14 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION
14.1 MIDDLE EAST AND AFRICA
14.1.1 SAUDI ARABIA
14.1.2 SOUTH AFRICA
14.1.3 U.A.E.
14.1.4 ISRAEL
14.1.5 KUWAIT
14.1.6 EGYPT
14.1.7 REST OF MIDDLE EAST AND AFRICA
15 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
16 SWOT ANALYSIS
17 COMPANY PROFILES
17.1 ABBOTT LABORATORIES
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENT
17.2 SIEMENS HEALTHINEERS AG
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENTS
17.3 QUEST DIAGNOSTICS INCORPORATED
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENT
17.4 THERMO FISHER SCIENTIFIC INC.
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.5 F.HOFFMAN-LA ROCHE LTD.
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT UPDATES
17.5.6 RECENT UPDATES
17.6 ACCUBIOTECH CO., LTD.
17.6.1 COMPANY SNAPSHOT
17.6.2 PRODUCT PORTFOLIO
17.6.3 RECENT DEVELOPMENT
17.7 ADVACARE PHARMA
17.7.1 COMPANY SNAPSHOT
17.7.2 PRODUCT PORTFOLIO
17.7.3 RECENT UPDATES
17.8 AGILENT TECHNOLOGIES, INC
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT UPDATES
17.9 ASSURE TECH (HANGZHOU) CO., LTD.
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENT
17.1 BD
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENT
17.11 BEIJING HOTGEN BIOTECHN CO., LTD.
17.11.1 COMPANY SNAPSHOT
17.11.2 PRODUCT PORTFOLIO
17.11.3 RECENT DEVELOPMENT
17.12 BIOEASY BIOTECHNOLOGY CO., LTD.,
17.12.1 COMPANY SNAPSHOT
17.12.2 PRODUCT PORTFOLIO
17.12.3 RECENT DEVELOPMENT
17.13 BIO-RAD LABORATORIES, INC.
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENT
17.14 CLIAWAIVED, INC.
17.14.1 COMPANY SNAPSHOT
17.14.2 PRODUCT PORTFOLIO
17.14.3 RECENT DEVELOPMENT
17.15 DRUGSCAN
17.15.1 COMPANY SNAPSHOT
17.15.2 PRODUCT PORTFOLIO
17.15.3 RECENT DEVELOPMENT
17.16 EGENS GROUP (NANTONG YISHI BIOTECHNOLOGY CO., LTD.)
17.16.1 COMPANY SNAPSHOT
17.16.2 PRODUCT PORTFOLIO
17.16.3 RECENT DEVELOPMENT
17.17 HANGZHOU ALLTEST BIOTECH CO.,LTD
17.17.1 COMPANY SNAPSHOT
17.17.2 PRODUCT PORTFOLIO
17.17.3 RECENT DEVELOPMENT
17.18 JOYSBIO (TIANJIN) BIOTECHNOLOGY CO., LTD
17.18.1 COMPANY SNAPSHOT
17.18.2 PRODUCT PORTFOLIO
17.18.3 RECENT UPDATES
17.19 LIFESIGN LLC.
17.19.1 COMPANY SNAPSHOT
17.19.2 PRODUCT PORTFOLIO
17.19.3 RECENT DEVELOPMENT
17.2 MERCK KGAA
17.20.1 COMPANY SNAPSHOT
17.20.2 REVENUE ANALYSIS
17.20.3 PRODUCT PORTFOLIO
17.20.4 RECENT DEVELOPMENTS
17.21 MP BIOMEDICALS
17.21.1 COMPANY SNAPSHOT
17.21.2 PRODUCT PORTFOLIO
17.21.3 RECENT DEVELOPMENT
17.22 PREMIER BIOTECH, INC.
17.22.1 COMPANY SNAPSHOT
17.22.2 PRODUCT PORTFOLIO
17.22.3 RECENT DEVELOPMENT
17.23 SYSMEX CORPORATION
17.23.1 COMPANY SNAPSHOT
17.23.2 REVENUE ANALYSIS
17.23.3 PRODUCT PORTFOLIO
17.23.4 RECENT DEVELOPMENTS
17.24 WONDFO
17.24.1 COMPANY SNAPSHOT
17.24.2 PRODUCT PORTFOLIO
17.24.3 RECENT DEVELOPMENT
17.25 XIAMEN BOSON BIOTECH CO., LTD.
17.25.1 COMPANY SNAPSHOT
17.25.2 PRODUCT PORTFOLIO
17.25.3 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
表のリスト
TABLE 1 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 2 MIDDLE EAST AND AFRICA AMPHETAMINES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 3 MIDDLE EAST AND AFRICA OPIATES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 4 MIDDLE EAST AND AFRICA CANNABINOIDS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 5 MIDDLE EAST AND AFRICA COCAINE IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 6 MIDDLE EAST AND AFRICA BARBITURATES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 7 MIDDLE EAST AND AFRICA BENZODIAZEPINES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 8 MIDDLE EAST AND AFRICA METHADONE IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 9 MIDDLE EAST AND AFRICA PHENCYCLIDINE IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 10 MIDDLE EAST AND AFRICA TRICYCLIC ANTIDEPRESSANTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 11 MIDDLE EAST AND AFRICA OTHERS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 12 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 13 MIDDLE EAST AND AFRICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 14 MIDDLE EAST AND AFRICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 15 MIDDLE EAST AND AFRICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 16 MIDDLE EAST AND AFRICA ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 17 MIDDLE EAST AND AFRICA IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 18 MIDDLE EAST AND AFRICA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 19 MIDDLE EAST AND AFRICA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 20 MIDDLE EAST AND AFRICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 21 MIDDLE EAST AND AFRICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 22 MIDDLE EAST AND AFRICA CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 23 MIDDLE EAST AND AFRICA CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 24 MIDDLE EAST AND AFRICA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 25 MIDDLE EAST AND AFRICA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 26 MIDDLE EAST AND AFRICA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 27 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 28 MIDDLE EAST AND AFRICA OVER THE COUNTER TESTING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 29 MIDDLE EAST AND AFRICA PRESCRIPTION-BASED TESTING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 30 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 31 MIDDLE EAST AND AFRICA URINE IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 32 MIDDLE EAST AND AFRICA SALIVA IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 33 MIDDLE EAST AND AFRICA BLOOD IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 34 MIDDLE EAST AND AFRICA HAIR IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 35 MIDDLE EAST AND AFRICA BREATH IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 36 MIDDLE EAST AND AFRICA OTHERS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 37 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 38 MIDDLE EAST AND AFRICA RANDOM TESTING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 39 MIDDLE EAST AND AFRICA POST-INCIDENT TESTING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 40 MIDDLE EAST AND AFRICA ABSTINENCE TESTING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 41 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 42 MIDDLE EAST AND AFRICA MEDICAL SCREENING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 43 MIDDLE EAST AND AFRICA WORKPLACE SCREENING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 44 MIDDLE EAST AND AFRICA LAW ENFORCEMENT AND CRIMINAL JUSTICE IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 45 MIDDLE EAST AND AFRICA PAIN MANAGEMENT IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 46 MIDDLE EAST AND AFRICA SUBSTANCE ABUSE TREATMENT AND REHABILITATION IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 47 MIDDLE EAST AND AFRICA PARENTAL OR HOME DRUG TESTING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 48 MIDDLE EAST AND AFRICA SPORTS AND ATHLETICS TESTING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 49 MIDDLE EAST AND AFRICA DRUG SCREENING IN SCHOOLS AND EDUCATIONAL INSTITUTIONS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 50 MIDDLE EAST AND AFRICA OTHERS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 51 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 52 MIDDLE EAST AND AFRICA HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 53 MIDDLE EAST AND AFRICA HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 54 MIDDLE EAST AND AFRICA EMPLOYERS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 55 MIDDLE EAST AND AFRICA GOVERNMENT INSTITUTES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 56 MIDDLE EAST AND AFRICA OTHERS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 57 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 58 MIDDLE EAST AND AFRICA DIRECT TENDER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 59 MIDDLE EAST AND AFRICA RETAIL SALES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 60 MIDDLE EAST AND AFRICA OTHERS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 61 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 62 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 63 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 64 MIDDLE EAST AND AFRICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 65 MIDDLE EAST AND AFRICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 66 MIDDLE EAST AND AFRICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 67 MIDDLE EAST AND AFRICA ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 68 MIDDLE EAST AND AFRICA IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 69 MIDDLE EAST AND AFRICA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 70 MIDDLE EAST AND AFRICA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 71 MIDDLE EAST AND AFRICA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 72 MIDDLE EAST AND AFRICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 73 MIDDLE EAST AND AFRICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 74 MIDDLE EAST AND AFRICA CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 75 MIDDLE EAST AND AFRICA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 76 MIDDLE EAST AND AFRICA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 77 MIDDLE EAST AND AFRICA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 78 MIDDLE EAST AND AFRICA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 79 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 80 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 81 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 82 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 83 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 84 MIDDLE EAST AND AFRICA HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 85 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 86 SAUDI ARABIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 87 SAUDI ARABIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 88 SAUDI ARABIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 89 SAUDI ARABIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 90 SAUDI ARABIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 91 SAUDI ARABIA ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 92 SAUDI ARABIA IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 93 SAUDI ARABIA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 94 SAUDI ARABIA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 95 SAUDI ARABIA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 96 SAUDI ARABIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 97 SAUDI ARABIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 98 SAUDI ARABIA CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 99 SAUDI ARABIA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 100 SAUDI ARABIA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 101 SAUDI ARABIA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 102 SAUDI ARABIA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 103 SAUDI ARABIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 104 SAUDI ARABIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 105 SAUDI ARABIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 106 SAUDI ARABIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 107 SAUDI ARABIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 108 SAUDI ARABIA HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 109 SAUDI ARABIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 110 SOUTH AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 111 SOUTH AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 112 SOUTH AFRICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 113 SOUTH AFRICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 114 SOUTH AFRICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 115 SOUTH AFRICA ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 116 SOUTH AFRICA IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 117 SOUTH AFRICA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 118 SOUTH AFRICA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 119 SOUTH AFRICA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 120 SOUTH AFRICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 121 SOUTH AFRICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 122 SOUTH AFRICA CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 123 SOUTH AFRICA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 124 SOUTH AFRICA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 125 SOUTH AFRICA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 126 SOUTH AFRICA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 127 SOUTH AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 128 SOUTH AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 129 SOUTH AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 130 SOUTH AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 131 SOUTH AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 132 SOUTH AFRICA HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 133 SOUTH AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 134 U.A.E. POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 135 U.A.E. POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 136 U.A.E. DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 137 U.A.E. DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 138 U.A.E. DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 139 U.A.E. ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 140 U.A.E. IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 141 U.A.E. BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 142 U.A.E. BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 143 U.A.E. BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 144 U.A.E. DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 145 U.A.E. DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 146 U.A.E. CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 147 U.A.E. ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 148 U.A.E. ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 149 U.A.E. ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 150 U.A.E. ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 151 U.A.E. POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 152 U.A.E. POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 153 U.A.E. POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 154 U.A.E. POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 155 U.A.E. POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 156 U.A.E. HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 157 U.A.E. POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 158 ISRAEL POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 159 ISRAEL POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 160 ISRAEL DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 161 ISRAEL DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 162 ISRAEL DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 163 ISRAEL ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 164 ISRAEL IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 165 ISRAEL BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 166 ISRAEL BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 167 ISRAEL BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 168 ISRAEL DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 169 ISRAEL DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 170 ISRAEL CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 171 ISRAEL ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 172 U.S. ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 173 U.S. ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 174 ISRAEL ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 175 ISRAEL ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 176 ISRAEL POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 177 ISRAEL POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 178 ISRAEL POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 179 SRAEL POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 180 ISRAEL POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 181 ISRAEL HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 182 ISRAEL POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 183 KUWAIT POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 184 KUWAIT POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 185 KUWAIT DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 186 KUWAIT DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 187 KUWAIT DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 188 KUWAIT ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 189 KUWAIT IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 190 KUWAIT BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 191 KUWAIT BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 192 KUWAIT BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 193 KUWAIT DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 194 KUWAIT DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 195 KUWAIT CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 196 KUWAIT ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 197 KUWAIT ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 198 KUWAIT ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 199 KUWAIT ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 200 KUWAIT ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 201 KUWAIT POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 202 KUWAIT POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 203 KUWAIT POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 204 KUWAIT POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 205 KUWAIT POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 206 KUWAIT HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 207 KUWAIT POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 208 EGYPT POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 209 EGYPT POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 210 EGYPT DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 211 EGYPT DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 212 EGYPT DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 213 EGYPT ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 214 EGYPT IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 215 EGYPT BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 216 EGYPT BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 217 EGYPT BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 218 EGYPT DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 219 EGYPT DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 220 EGYPT CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 221 EGYPT ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 222 EGYPT ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 223 EGYPT ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 224 EGYPT ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 225 EGYPT POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 226 EGYPT POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 227 EGYPT POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 228 EGYPT POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 229 EGYPT POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 230 EGYPT HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 231 EGYPT POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 232 REST OF MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
図表一覧
FIGURE 1 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: END USER COVERAGE GRID
FIGURE 8 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: SEGMENTATION
FIGURE 11 TEN SEGMENTS COMPRISE THE MIDDLE EAST AND AFRICA POINT-OF-CARE DRUG ABUSE TESTING MARKET, BY DRUG TYPE
FIGURE 12 EXECUTIVE SUMMARY
FIGURE 13 STRATEGIC DECISIONS
FIGURE 14 RISING INCIDENCE OF DRUG ABUSE IS DRIVING THE GROWTH OF THE MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET FROM 2024 TO 2031
FIGURE 15 THE AMPHETAMINES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOB POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET IN 2024 AND 2031
FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET
FIGURE 17 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DRUG TYPE, 2023
FIGURE 18 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DRUG TYPE, 2024-2031 (USD THOUSAND)
FIGURE 19 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DRUG TYPE, CAGR (2024-2031)
FIGURE 20 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 21 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRODUCTS 2023
FIGURE 22 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRODUCTS, 2024-2031 (USD THOUSAND)
FIGURE 23 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRODUCTS, CAGR (2024-2031)
FIGURE 24 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRODUCTS, LIFELINE CURVE
FIGURE 25 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRESCRIPTION, 2023
FIGURE 26 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRESCRIPTION, 2024-2031 (USD THOUSAND)
FIGURE 27 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRESCRIPTION, CAGR (2024-2031)
FIGURE 28 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRESCRIPTION, LIFELINE CURVE
FIGURE 29 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY SAMPLE TYPE, 2023
FIGURE 30 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY SAMPLE TYPE, 2024-2031 (USD THOUSAND)
FIGURE 31 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY SAMPLE TYPE, CAGR (2024-2031)
FIGURE 32 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY SAMPLE TYPE, LIFELINE CURVE
FIGURE 33 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY TESTING TYPE, 2023
FIGURE 34 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY TESTING TYPE, 2024-2031 (USD THOUSAND)
FIGURE 35 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY TESTING TYPE, CAGR (2024-2031)
FIGURE 36 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET : BY TESTING TYPE, LIFELINE CURVE
FIGURE 37 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY APPLICATION, 2023
FIGURE 38 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY APPLICATION, 2024-2031 (USD THOUSAND)
FIGURE 39 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY APPLICATION, CAGR (2024-2031)
FIGURE 40 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 41 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY END USER, 2023
FIGURE 42 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY END USER, 2024-2031 (USD THOUSAND)
FIGURE 43 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY END USER, CAGR (2024-2031)
FIGURE 44 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY END USER, LIFELINE CURVE
FIGURE 45 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 46 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD THOUSAND)
FIGURE 47 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 48 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 49 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: SNAPSHOT (2023)
FIGURE 50 MIDDLE EAST AND AFRICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: COMPANY SHARE 2023 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
